Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiuLMLixia MaYGYuelu Guo

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows TP53 mutations did not significantly affect outcomes in CAR-T therapy for large B-cell lymphoma, indicating potential resistance mitigation.

Key Points

  • Overall response rate in CAR-T patients was 49.3%, highlighting the therapy's effectiveness in large B-cell lymphoma.
  • Statistical analysis employed log-rank tests and univariate analysis to assess survival outcomes post-treatment.
  • Cytokine release syndrome occurred in 81.6% of CAR-T patients, indicating significant treatment-related toxicity.
  • TP53 mutations appear less detrimental to prognosis in the context of CAR-T therapy, with further validation needed.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec5https://doi.org/10.1182/blood-2025-3706
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025
  2. 2Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.2025 · 2 citations
  3. 3Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2025
  4. 4CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier2025
  5. 5Concurrent TP53 loss-of-function and epigenetic modifier mutations as a potential predictor of chemoimmunotherapy failure in DLBCL & hgbl2025